Literature DB >> 10877569

Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast.

J Bryant, A Clegg, R Milne.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10877569      PMCID： PMC1127655     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  7 in total

1.  Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis.

Authors:  R B Forbes; A Lees; N Waugh; R J Swingler
Journal:  BMJ       Date:  1999-12-11

2.  Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.

Authors:  Y Ben-Shlomo; A Churchyard; J Head; B Hurwitz; P Overstall; J Ockelford; A J Lees
Journal:  BMJ       Date:  1998-04-18

3.  Problems of using modelling in the economic evaluation of health care.

Authors:  T A Sheldon
Journal:  Health Econ       Date:  1996 Jan-Feb       Impact factor: 3.046

4.  A cost-utility analysis of interferon beta for multiple sclerosis.

Authors:  D Parkin; P McNamee; A Jacoby; P Miller; S Thomas; D Bates
Journal:  Health Technol Assess       Date:  1998       Impact factor: 4.014

5.  Sleep apnoea and the misuse of evidence-based medicine.

Authors:  M Kryger
Journal:  Lancet       Date:  1997-03-15       Impact factor: 79.321

6.  Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.

Authors: 
Journal:  Lancet       Date:  1998-11-07       Impact factor: 79.321

7.  Gains in life expectancy from medical interventions--standardizing data on outcomes.

Authors:  J C Wright; M C Weinstein
Journal:  N Engl J Med       Date:  1998-08-06       Impact factor: 91.245
  7 in total
  2 in total

1.  Drug treatment of multiple sclerosis. Clinical review was unsystematic.

Authors:  R Milne; A Clegg; J Bryant
Journal:  BMJ       Date:  2001-02-03

2.  Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost?

Authors:  J Bryant; A Clegg; R Milne
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.